Semax

Semax is derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension that confers protease resistance. Unlike ACTH, it does not stimulate adrenal steroidogenesis. Proposed mechanisms include: increased BDNF and NGF expression in the hippocampus and cortex, modulation of serotonergic and dopaminergic neurotransmission, enhancement of adaptive neuroplasticity, anti-inflammatory effects via inhibition of NO synthesis and pro-inflammatory cytokines, and improvement of cerebral microcirculation. It crosses the blood-brain barrier via intranasal administration.

Clinical evidence comes primarily from Russian literature. Several controlled trials in Russia have demonstrated benefits in acute ischemic stroke (improved neurological outcomes at 3-6 months), cognitive disorders associated with cerebrovascular disease, and optic nerve atrophy. These studies led to Russian regulatory approval. However, these trials generally do not meet Western standards for trial methodology, reporting, and peer review. No clinical trials have been conducted under FDA or EMA oversight. Preclinical data supporting BDNF upregulation and neuroprotection are more robust and published in Western journals.

Semax is approved in Russia and several CIS countries for ischemic stroke, cognitive disorders, and optic nerve atrophy. It is not approved by the FDA, EMA, or any Western regulatory authority. It is available in the grey market internationally. No established regimen by Western standards; consult clinician; research-only risks apply in non-approved jurisdictions.

No established Western monitoring protocols. In Russian clinical practice, neurological assessment and cognitive testing are used to track treatment response. General monitoring for mood changes or anxiety may be appropriate given the neurotransmitter-modulating effects.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

Nasal spray formulation. Russian pharmaceutical preparations should be stored refrigerated. Grey-market products vary in formulation and stability. Peptide is susceptible to degradation if not properly stored.

1. 1

   RCT

   Neuroprotective Effects of Semax in Acute Ischemic Stroke

   Gusev EI, Skvortsova VI, et al. (2005). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

   Key findings: Russian controlled trial showing improved neurological outcomes at 3 and 6 months in acute ischemic stroke patients treated with intranasal Semax.

   Limitations: Russian language publication. Trial methodology may not meet Western standards.

2. 2

   preclinical

   ACTH(4-10) Analogue Semax Stimulates BDNF Expression in the Rat Hippocampus

   Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Brain Research

   Key findings: Semax increased BDNF mRNA expression in the hippocampus and cortex of rats, suggesting a mechanism for neuroprotective and nootropic effects.

   Limitations: Animal study. Dose and route may not translate to human use.

3. 3

   review

   Semax and Selank: Regulatory Peptides with Nootropic and Anxiolytic Properties

   Myasoedov NF, et al. (2016). Neurochemical Journal

   Key findings: Review of both peptides covering mechanisms, clinical data from Russian studies, and regulatory status.

   Limitations: Review by the development group. Primarily Russian clinical data.